Presentazione sul tema: "Workshop 1: Lanziano Moderatori: E. Sagnelli, F. Suter Discussant: F.v. Schloesser La complessità della gestione terapeutica dellanziano a lungo termine."— Transcript della presentazione:
Workshop 1: Lanziano Moderatori: E. Sagnelli, F. Suter Discussant: F.v. Schloesser La complessità della gestione terapeutica dellanziano a lungo termine A. Castagna
Guidelines and clinical expertise: the italian algorithm to build the future with the patient La complessità della gestione terapeutica dellanziano a lungo termine Antonella Castagna IRCCS San Raffaele Roma 15 dicembre 2010
Prevalence of HIV associated type 2 diabetes in comparison with the italian population P=0.0006 P<0.0001 P=0.153 P=0.002 P<0.0001 55091431 58773185 HIV+ HIV- <=50>50Number of pts L. Galli, in preparation
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes The ACCORD Study Group and ACCORD Eye Study Group In a randomized trial, we enrolled 10,251 participants with type 2 diabetes who were at high risk for cardiovascular disease to receive either intensive or standard treatment for glycemia (target glycated hemoglobin level, <6.0% or 7.0 to 7.9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg). A subgroup of 2856 participants was evaluated for the effects of these interventions at 4 years on the progression of diabetic retinopathy Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy NEJM 2010
Clinical inertia Recognising the problem but failure to act Clinical inertia, defined as a failure to initiate or advance therapy in a patient who is not at the evidence-based goal, is a key contributing factor in the suboptimal rates of therapeutic target achievement for type 2 diabetes. The causes of clinical inertia are multifactorial and interactive, arising among patients, providers, and health systems and from specific characteristics of available treatments. Therapeutic non adherence is perhaps the most significant factor contributing to clinical inertia, with recent analyses demonstrating that providers are more likely to prescribe a dose escalation in patients who are adherent to therapy compared with those who are not.
Only high adherers reported a significantly decreased risk of acute cardiovascular events (HR 0.62) Mazzaglia G, Circulation 2010